Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Avid Bioservices, Inc. CDMOP
$25.06
На 18:01, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
31.95
-
week52low
23.35
-
Revenue
95868000
-
P/E TTM
126
-
Beta
2.69645800
-
EPS
-0.00400000
-
Last Dividend
18.66760000
-
Next Earnings Date
07 мая 2023 г. в 02:07
Описание компании
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, purification, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. Avid Bioservices, Inc. has a process development and manufacturing agreement with Oragenics, Inc. to develop coronavirus vaccine. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was founded in 1981 and is headquartered in Tustin, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | 17 мар 2021 г. | |
| KeyBanc | Overweight | 10 ноя 2020 г. | |
| H.C. Wainwright | Buy | 11 мар 2020 г. | |
| Stephens & Co. | Overweight | 10 дек 2019 г. | |
| First Analysis | Strong Buy | Outperform | 10 дек 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Green Nicholas Stewart | D | 76615 | 7493 | 10 окт 2022 г. |
| Hart Daniel R | D | 47020 | 1262 | 10 окт 2022 г. |
| Ziebell Mark R | D | 44646 | 1260 | 09 окт 2022 г. |
| Ziebell Mark R | D | 45906 | 697 | 09 окт 2022 г. |
| Ziebell Mark R | A | 37275 | 1260 | 09 окт 2022 г. |
| Ziebell Mark R | A | 36015 | 697 | 09 окт 2022 г. |
| Green Nicholas Stewart | D | 268701 | 8826 | 09 окт 2022 г. |
| Green Nicholas Stewart | D | 277527 | 5574 | 09 окт 2022 г. |
| Green Nicholas Stewart | A | 84108 | 8826 | 09 окт 2022 г. |
| Green Nicholas Stewart | A | 75282 | 5574 | 09 окт 2022 г. |
Новостная лента
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023
GlobeNewsWire
06 мар 2023 г. в 16:05
TUSTIN, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the third quarter of fiscal year 2023 on March 13, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the third quarter and review recent corporate developments.
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
GlobeNewsWire
29 ноя 2022 г. в 16:05
TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.
Avid Bioservices to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
GlobeNewsWire
07 сент 2022 г. в 16:05
TUSTIN, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place September 12-14, 2022, in New York City.
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2023 After Market Close on September 6, 2022
GlobeNewsWire
30 авг 2022 г. в 16:05
TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2023 on September 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2022 After Market Close on June 29, 2022
GlobeNewsWire
22 июн 2022 г. в 16:05
TUSTIN, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2022 on June 29, 2022 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2022 and review recent corporate developments.